Nvwm LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Nvwm LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,554 shares of the company’s stock after purchasing an additional 151 shares during the quarter. Nvwm LLC’s holdings in Zoetis were worth $1,476,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Quarry LP increased its holdings in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares during the last quarter. Fortitude Family Office LLC grew its position in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the period. LRI Investments LLC purchased a new stake in shares of Zoetis in the 1st quarter worth $43,000. Central Valley Advisors LLC purchased a new stake in shares of Zoetis in the 2nd quarter worth $49,000. Finally, Future Financial Wealth Managment LLC bought a new position in Zoetis in the 3rd quarter worth $59,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS traded up $3.17 on Friday, reaching $181.95. The company had a trading volume of 2,838,633 shares, compared to its average volume of 1,795,404. The stock has a market capitalization of $82.43 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The firm’s 50 day moving average price is $188.97 and its 200 day moving average price is $178.69.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the business earned $1.41 earnings per share. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, equities analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.95%. Zoetis’s dividend payout ratio is currently 33.66%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of analyst reports. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.